<DOC>
	<DOCNO>NCT00801060</DOCNO>
	<brief_summary>This Phase 2 , randomize , open-label , multicenter study subject previously untreated CLL . It design evaluate safety efficacy fludarabine , cyclophosphamide , rituximab ( FCR ) lumiliximab versus FCR alone .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Fludarabine , Cyclophosphamide , Rituximab ( FCR ) +/- Lumiliximab Subjects With Previously Untreated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>See protocol .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 year old . Previously untreated CD23+ CD20+ B cell CLL . Life expectancy &gt; 6 month . Subjects Rai Stage III IV ( Binet Stage C ) Rai Stage I II ( Binet Stage A B ) determine active disease . World Health Organization ( WHO ) Performance Status ≤2 . Normal ECG QTc ≤450 msec men ≤460 msec woman . PR interval ( Print ) must &lt; 240 msec QRS complex &lt; 110 msec . T wave flatten T wave inversion permit . All male subject female subject childbearing potential must practice effective contraception study willing able continue contraception 12 month last dose study treatment . Acceptable liver function Screening . Acceptable hematologic status Screening . Acceptable renal function Screening . Subjects receive medication know affect QTc interval must discontinue use medication stable dose medication least 3 month 5 halflives ( whichever longer ) prior Study Day 1 , continue ( whenever possible ) dose throughout study . EXCLUSION CRITERIA : Any prior therapy CLL . Known history positive test result human immunodeficiency virus . Known history , positive test result Hepatitis C virus ( test Hepatitis C virus antibody ) Hepatitis B virus ( test Hepatitis B Surface Antigen Hepatitis B Core Antibody ) Screening . Uncontrolled diabetes mellitus . Uncontrolled hypertension . Hypokalemia . Hypomagnesemia . New York Heart Association Class III IV cardiac disease ; myocardial infarction within past 6 month prior Study Day 1 . Arrhythmia ( sinus arrhythmia ) within 30 day prior Study Day 1 . Evidence active myocardial ischemia ECG . Subjects pacemaker . Transformation aggressive Bcell malignancy . Secondary malignancy require active treatment . Any medical condition would require longterm use ( &gt; 1 month ) systemic corticosteroid study treatment . Any serious nonmalignant disease laboratory abnormality , would confound evaluation adverse event ( AEs ) . Active bacterial , viral , fungal infection . Any known family history long QT syndrome . Seizure disorder require anticonvulsant therapy . Severe chronic obstructive pulmonary disease hypoxemia . Major surgery , diagnostic surgery , within 4 week prior Study Day 1 . Clinically active autoimmune disease . Presence history Coombs positive hemolytic anemia . Pregnant currently breastfeed Screening . Prior exposure lumiliximab anti CD23 antibody . Subjects know hypersensitivity Chinese hamster ovary cell protein , murine protein , component fludarabine , cyclophosphamide , rituximab , lumiliximab investigational treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Fludara</keyword>
	<keyword>CD23</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Antibody</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>CLL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Mabthera</keyword>
	<keyword>Biogen Idec</keyword>
	<keyword>Lumiliximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>